DJIA 17,001.22 -38.27 -0.22%
NASDAQ 4,538.55 6.45 0.14%
S&P 500 1,988.40 -3.97 -0.20%
market minute promo

MannKind Corp (NASDAQ: MNKD)

company name or ticker

Osiris Stem Cells To Compliment Mannkind's Afrezza In Disrupting Diabetes Market

MannKind: Let It Dip A Bit More, Then Cover/Buy

Mannkind Corporation: Safe Labeling, Incentivized Spirometry and Experts Votes of Confidence

MannKind: Why The Short Argument Is Shortsighted

MannKind Afrezza Partnership News Coming Within Weeks

MannKind Corporation: Investors Should Seek Truth As The Requisite To Finding This Alpha

Will FDA Labelling Be MannKind's Downfall?

While FDA approval may have come wrapped in a pretty box for shareholders, what is inside the box in terms of FDA warnings could be a huge problem for MannKind and Afrezza.

AFREZZA Is A Brilliant Technology Without A Compelling Marketing Story

3 Longtime Losers About to See Green?

These 3 biotechs have lost tons of money every year so far in the 21st century. But could profits be on the horizon?

Top Swing Trade Ideas for Monday July 21: Cliffs Natural Resources, MannKind, PolyOne

See More Articles...